Open AccessHealth Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study
Author(s) -
Tim M J Ewoldt,
Alan Abdulla,
Nicole Hunfeld,
Anouk E. Muller,
Diederik Gommers,
Suzanne Polinder,
Birgit C. P. Koch,
Henrik Endeman
Publication year - 2021
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000891
Subject(s) - intensive care unit , antibiotics , medicine , renal replacement therapy , critically ill , beta lactam , intensive care medicine , emergency medicine , indirect costs , cost analysis , economics , microbiology and biotechnology , engineering , accounting , reliability engineering , biology
Optimizing beta-lactam antibiotic treatment is a promising method to reduce the length of intensive care unit (ICU) stay and therefore reduce ICU costs. We used data from the EXPAT trial to determine whether beta-lactam antibiotic target attainment is a cost determinant in the ICU.